Geriatric Medicine Doctors in Rye Brook, NY - Medicare Status, Address, Contact

1 Geriatric Medicine doctors found. Showing 1 - 1

Dr. Roger Scott Madris, M.D.
Internal Medicine - Geriatric Medicine
Medicare: Medicare Enrolled
Practice Location: 14 Rye Ridge Plz, Suite 151, Rye Brook, NY 10573
Phone: 914-253-6504 Fax: 914-253-6507

News Archive

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

Study shows promising results for cancer treatment

The plasma membrane transporter SLC5A8 can inhibit the spread of tumours by decreasing the amount of the anti-apoptotic protein surviving in tumour cells.

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived, according to clinical researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Brigham and Women's Hospital. This is comparable to the rate of eventual pregnancy among all clinically infertile women.

Understanding emotional reactions for negative services

Service quality beliefs are usually positively related to customer satisfaction - the higher the perceived service quality, the higher the customer's satisfaction. However, an article published in the August issue of the Journal of Service Research finds this relationship may be more complicated in "negative service environments" (i.e., services that consumers would prefer not to have to use), such as health screening, diagnostic tests, or even auto repair.

Alnara Pharmaceuticals' announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

Geriatric Medicine Doctors in Rye Brook, NY Accepting Medicare